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In a monocentric and prospective study involving 96 consecutive patients (stable angina:
28; unstable angina: 30 and recent myocardial infarction: 38) referred to PCI revasculari-
sation, we determined the concentrations of serum MMP 2-9 and TIMP 1-2. Each patient
was treated with one or more non-drug eluting stent, with or without balloon-predilatation.
Blood was sampled from aorta before and immediately post-PCI and from venous access
24 hours later (J1). MMPs plasma concentrations were measured by enzyme-linked
immunoabsorbent assay. Follow-up (15.4 ± 3.2 months) documented the occurrence of
reintervention, myocardial infarction (MI) and death. Value are expressed as mean ±
SEM.
Results:
About MMP2 plasma level, there was a trend to higher values after PCI followed by a
decrease at J1. Those variations did not reached the significant level. By contrast,
MMP9, TIMP 2-9 were significantly lower after PCI then increased significantly at J1, for
the whole population and the3 different subgroup of clinical status. Despite non signifi-
cant variation for the whole population and subgroups, post-PCI MMP2 plasma level cor-
related with reintervention (p: 0.0003). Furthermore, a positive variation of MMP2
between pre and post-PCI (p: 0.0003) as well as a negative variation of MMP 2 between
post-PCI and J1 (p: 0.0009) correlated both with reintervention.
Conclusions:
Variations of MMPs and inhibitors immediately after PCI can be documented through
conventional vessel access. MMP2 kinetic after stent implantation allows interesting
information regarding the risk of reintervention.
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Background. Cerebrovascular and peripheral arterial diseases frequently coexist in pts
with coronary artery disease (CAD).Whether the presence of cerebrovascular disease
(CVD) alone or in combination with peripheral arterial disease (PAD) influences the out-
comes of percutaneous coronary intervention (PCI) is not known. We compared the
impact of symptomatic CVD and/or PAD on the prognosis of pts undergoing PCI. Meth-
ods and Results. Of 10,428 pts, symptomatic CVD, PAD, or both were identified in 743
(7.1%), 1,541 (14.8%) and 424 (4.1%) pts, respectively. Compared to the remaining
7,720 pts without these conditions (controls), pts with CVD, PAD, or both were older,
more frequently female, and had lower ejection fraction. Pts with CVD, PAD, or both had
higher than controls rates of in-hospital mortality (2.8%, 2.0%, and 2.4%, respectively, vs
0.9%, P<0.0001), stroke (0.8%, 0.5%, and 1.2% vs 0.2%, P=0.0015), and limb ischemia
(1.6%, 3.0%, and 3.1% vs 0.6%, P<0.0001). One-year outcomes were significantly worse
in pts with CVD, PAD, or both than in controls (Table). By multivariate analysis, CVD was
an independent predictor of in-hospital mortality (odds ratio=2.29, P=0.0031). One-year
mortality was predicted by either CVD (odds ratio=1.44, P=0.02) or PAD (odds
ratio=1.76, P<0.0001); but the two were not additive. Conclusions: Symptomatic CVD
and/or PAD are associated with adverse in-hospital and 1-year outcomes and indepen-
dently predict in-hospital and/or 1-year mortality.
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Background: Percutaneous transluminal coronary angioplasty (PTCA) is limited by the
recurrence of luminal stenosis. This study evaluated the incidence and risk factors of clin-
ical restenosis in an unselected patient population with contemporary intervention tech-
niques in the pre-Drug Eluting Stent (DES) era.
Methods: The GEnetic DEterminants of Restenosis (GENDER) project was a multi-
center prospective cohort study, which included 3,146 patients after successful PTCA.
Patients with acute myocardial infarction (MI) were excluded.
Results: A total of 3,146 patients (age 62.1±10.7 yrs) were followed for 10±3 months. Of
the patients 2,250 (71.5%) were male, 459 (14.6%) had diabetes and 1,459 (46.4%) had
multivessel disease. The majority was treated for stable angina. Stenting was performed
in 2,340 (74.4%) patients and IIb/IIIa inhibitors were used in 820 (26.1%) patients. Target
vessel revascularization after the first month by either CABG or PTCA was necessary in
304 patients (9.7%). Thirty-three (1.1%) died of cardiac disease and 22 (0.7%) suffered
from MI attributable to the originally treated vessel. Overall a need for revascularization,
cardiac death or MI occurred in 346 patients (11.0%). After correction for all baseline
characteristics in a multivariate analysis; diabetes, hypertension, peripheral vessel dis-
ease, multivessel disease and treatment of type C lesions prevailed as independent risk
factors for clinical restenosis. After dividing the patients into subgroups depending upon
the number of risk factors present in these patients, we constructed six subgroups. Group
one had zero or one risk factor (n=700) and a clinical restenosis rate of 7.6%, whereas
group three, with four or five risk factors (n=386) had a rate of 17.3% after one year fol-
low-up.
Conclusion: In this unselected series of patients clinical restenosis occurred in only
11.0%. Proper selection of patients that benefit from new devices is warranted, since the
vast majority is well treated with standard techniques. Although patients with more clini-
cal risk factors show a higher restenosis rate, it remains difficult to predict events.
Genetic determinants may have additional value for stratifying patients at risk.
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Background: Although the development in the techniques and devices for PCI has
reduced the restenosis rate, restenosis has not been completely prevented and its risk
factors have not been thoroughly clarified. Progression of atherosclerosis is known to
increase the inflammation and thrombus formation, which may promote restenosis.
Therefore, we tested if angioscopically determined extent of atherosclerosis could be a
risk factor of restenosis.
Methods: Among 1050 patients of ischemic heart disease who received PCI, angioscopic
evaluation of coronary atherosclerosis was performed in 263 patients. Target vessel was
observed by angioscopy and the color of plaques was graded as 0 (white), 1 (slight yel-
low), 2 (yellow), or 3 (intensive yellow). The extent of atherosclerosis was assessed by
the number of yellow plaques (N), maximum (MC) and sum (SC) of color grade of
observed plaques. The rate of target vessel revascularization (TVR) was used as the
marker of restenosis.
Results: TVR of all 1050 patients was 19%, and of all 263 patients who received angio-
scopic examination was 16%. TVR increased according to the increase in N (N3, 29%),
MC (MC=1, 10%; MC=2, 16%; MC=3, 23%), and SC (SC<3, 16%; SC>3, 23%; SC>5,
25%; SC>7, 27%; SC>9, 29%). Repeat TVR also increased according to the increase in
N (N=0/1, 0%; N=2, 9%; N>3, 21%), MC (MC=0/1, 0%; MC=2, 11%; MC=3, 29%), and
SC (SC=0/1, 0%; SC=2/3, 6%; SC>4, 24%).
Conclusions: Angioscopically determined extent of coronary atherosclerosis according to
the number of yellow plaques and the yellow color intensity of plaques is a risk factor of
restenosis.
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Background:
The role of inflammation in acute coronary syndrome is well established. Recent studies
suggest that elevated admission white blood cell count (WBC) is associated with adverse
outcomes in patients undergoing PCI for acute myocardial infarction (AMI).
Hypothesis:
Peak rather than admission WBC in patients undergoing PCI for AMI is a better marker of
the magnitude of inflammation and thus more accurately predicts adverse long term out-
come.
Methods:
Prospectively collected data on consecutive patients undergoing PCI for AMI was
obtained from the American College of Cardiology-National Cardiovascular Data Regis-
try. Patients were divided into 5 strata based on WBC. Three years follow up data for
major adverse cardiac events was analyzed.
Results:
There were 496 patients including 260/496 (52.42%) patients with ST elevation AMI and
236/496 (47.58%) patients with non ST elevation AMI. The peak WBC ranged from 3.8 to
44.9 X109/L. The admission WBC ranged from 2.4 to 31.6 X109/L. Baseline characteris-
tics including age, gender and cardiac risk factors were not significantly different among
groups. High peak WBC was associated with higher mortality (p <0.0001) while elevated
admission WBC failed to show statistically significant relationship to outcome.
Conclusion:
WBC count, a readily available inflammatory marker is useful in stratifying low Vs high-
risk patients with AMI undergoing PCI.
Elevated peak WBC count could select patients for more aggressive therapeutic strate-
gies. 
One-Year Outcomes
Endpoint, % (+)CVD
(-)PAD
N=743
(-)CVD
(+)PAD
N=1541
(+)CVD
(+)PAD
N=424
(-)CVD
(-)PAD
N=7720
P-value*
Death 9.9 12.6 16.7 4.7 <0.0001
Q-wave MI 1.5 1.0 2.3 1.2 0.19
Non-Q wave MI 6.6 6.3 9.4 5.2 0.004
TVR 21.5 25.0 23.1 21.2 0.02
*Chi-square statistics
